Press Release Archive

(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard chemotherapy regimen, in patients with metastatic colorectal cancer (mCRC) - cancer originating in the colon that has spread to other parts of the body. In addition, new data from a Phase I study being presented this week at the World Congress on Gastrointestinal

(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took Exubera® (insulin human [rDNA origin]) Inhalation Powder reversed when Exubera was discontinued. Upon re-initiation of Exubera, lung function changes similar to first time users of Exubera were observed. The studies also showed that patients on an Exubera

(BUSINESS WIRE)--Pfizer announced today the U.S. Food and Drug Administration (FDA) issued an approvable letter for maraviroc, which is under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. We continue our discussions with the FDA to address outstanding questions and finalize the product labeling as soon as possible. Pfizer is committed to making maraviroc available to the thousands of patients

(BUSINESS WIRE)-- Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first and only FDA-approved veterinary medication for the management of canine obesity, is now available by prescription in the United States. Slentrol was developed in response to the unmet need for a medication to help veterinarians and pet owners better manage canine obesity, an important medical condition that can lead

(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago. The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year: Compound

(BUSINESS WIRE)--Pfizer announced today that single-agent, oral SUTENT® (sunitinib malate) prolonged progression-free survival (PFS) across all patient risk groups, including those with the poorest prognoses for survival versus interferon-alfa (IFN-α), according to new data from the Phase III trial in the first-line treatment of advanced renal cell carcinoma (RCC). These data, along with Phase II studies of SUTENT in several tumor

(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s participation in Express Scripts’ rebate program. Due to improved terms under the agreement, Express Scripts has added Lipitor® (atorvastatin calcium), Pfizer’s treatment for high cholesterol and the reduction of heart attack and stroke, to its national preferred

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Monday, June 4, at 6:00 p.m. Central Daylight Savings Time, in connection with the Annual Meeting of the American Society of Clinical Oncology (ASCO). The analyst meeting will include presentations by Pfizer’s oncology leadership team. To view the webcast, visit our web site

(BUSINESS WIRE)--Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC) and renal cell carcinoma (RCC) – a type of advanced kidney cancer – will be presented next week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. “Each person with cancer responds differently to treatment